Abstract
Intravitreal triamcinolone and bevacizumab are emerging treatment modalities for the patients of macular oedema; however, they are known to raise intraocular pressure. A 61 year old diabetic male patient developed glaucoma after administration of triamcinolone acetonide and bevacizumab intravitreally for treatment of macular oedema. His intraocular pressure was raised up to about 42 mm Hg. Such high and sustained rise in intraocular pressure may lead to vision loss by damaging the optic nerve. The patient was managed by local as well as systematic therapy and was recovered after 1 month from the occurrence of an event. Intraocular pressure should be monitored in patients receiving intravitreal triamcinolone and bevacizumab. Risk benefit analysis must be done before using IVTA and IVB in patients with diabetic macular oedema.
Keywords: Triamcinolone acetonide, bevacizumab, intraocular pressure, diabetes mellitus, adverse drug reaction.
Current Drug Safety
Title:Triamcinolone Acetonide and Bevacizumab Induced Raised Intraocular Pressure in An Elderly Male Diabetic Patient - A Case Report
Volume: 11 Issue: 3
Author(s): Hiral N. Golakiya, Hiren N. Hirapara, Sugnesh J. Parmar, Viren N. Naik and Chandrabhanu B. Tripathi
Affiliation:
Keywords: Triamcinolone acetonide, bevacizumab, intraocular pressure, diabetes mellitus, adverse drug reaction.
Abstract: Intravitreal triamcinolone and bevacizumab are emerging treatment modalities for the patients of macular oedema; however, they are known to raise intraocular pressure. A 61 year old diabetic male patient developed glaucoma after administration of triamcinolone acetonide and bevacizumab intravitreally for treatment of macular oedema. His intraocular pressure was raised up to about 42 mm Hg. Such high and sustained rise in intraocular pressure may lead to vision loss by damaging the optic nerve. The patient was managed by local as well as systematic therapy and was recovered after 1 month from the occurrence of an event. Intraocular pressure should be monitored in patients receiving intravitreal triamcinolone and bevacizumab. Risk benefit analysis must be done before using IVTA and IVB in patients with diabetic macular oedema.
Export Options
About this article
Cite this article as:
Golakiya N. Hiral, Hirapara N. Hiren, Parmar J. Sugnesh, Naik N. Viren and Tripathi B. Chandrabhanu, Triamcinolone Acetonide and Bevacizumab Induced Raised Intraocular Pressure in An Elderly Male Diabetic Patient - A Case Report, Current Drug Safety 2016; 11 (3) . https://dx.doi.org/10.2174/1574886311666160405110246
DOI https://dx.doi.org/10.2174/1574886311666160405110246 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drug Delivery to the Posterior Segment of the Eye: Challenges and Opportunities
Drug Delivery Letters Neuroprotective Effects of Drug-Induced Therapeutic Hypothermia in Central Nervous System Diseases
Current Drug Targets Plasticity and Maintenance of Hematopoietic Stem Cells During Development
Recent Patents on Biotechnology Review of Endocrine Manifestations of Antiphospholid Syndrome
Current Rheumatology Reviews Cerebrovascular Amyloidosis and Dementia
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Safety and Efficacy of Dexamethasone Intravitreal Implant (Ozurdex) for the Treatment of Persistent Macular Edema Secondary to Retinal Vein Occlusion in Eyes Previously Treated with Anti-Vascular Endothelial Growth Factors
Current Drug Safety Anti-angiogenic Drugs as an Adjunctive Therapy in the Surgical Treatment of Diabetic Retinopathy
Current Diabetes Reviews Anti-Vegf Therapy for Ocular Diseases: Present and Future
Current Drug Targets Toxins Targeting Voltage-Activated Ca<sup>2+</sup> Channels and their Potential Biomedical Applications
Current Topics in Medicinal Chemistry Proliferative Retinopathies: Animal Models and Therapeutic Opportunities
Current Neurovascular Research Vascular Damage in Impaired Glucose Tolerance: An Unappreciated Phenomenon?
Current Pharmaceutical Design Matrix Gelatinases in Atherosclerosis and Diabetic Nephropathy: Progress and Challenges
Current Vascular Pharmacology Stem Cells Derived from Human Exfoliated Deciduous Teeth (SHED) in Neuronal Disorders: A Review
Current Stem Cell Research & Therapy Pharmacogenomics of Open-Angle Glaucoma
Current Pharmacogenomics and Personalized Medicine Modeling Loss of Microvascular Wall Homeostasis during Glycocalyx Deterioration and Hypertension that Impacts Plasma Filtration and Solute Exchange
Current Neurovascular Research Cerebral Vascular Aging: Extending the Concept of Pulse Wave Encephalopathy Through Capillaries to the Cerebral Veins
Current Aging Science Impact of Omega-3 and Trans Fatty Acids on Vascular Remodeling:Opposing Roles in Cardiovascular Health
Current Enzyme Inhibition AMPK as a New Attractive Therapeutic Target for Disease Prevention: The Role of Dietary Compounds AMPK and Disease Prevention
Current Drug Targets Inhibitors of Nitric Oxide Synthase: What's up and What's Next?
Current Enzyme Inhibition Role of Ischemic Blood-Brain Barrier on Amyloid Plaques Development in Alzheimers Disease Brain
Current Neurovascular Research